Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Use of haloperidol ups risk of in-hospital death in patients with acute MI

Stephen Padilla
16 Apr 2018

Initiating oral haloperidol instead of an oral atypical antipsychotic in patients with acute myocardial infarction (MI) is associated with a small increased risk of death within 7 days, reports a new study. The increased risk is strongest during the first 4 days and no longer evident by day 5 of follow-up.

“[A]lthough haloperidol has long been used to manage agitation or related symptoms for patients admitted to hospital, our findings suggest that atypical antipsychotics may be a less harmful option in older populations with acute myocardial infarction who require an off-label antipsychotic for severe agitation,” researchers said.

A total of 6,578 patients (mean age 75.2 years) treated with an oral antipsychotic drug, of whom 1,668 (25.4 percent) initiated haloperidol and 4,910 (74.6 percent) initiated atypical antipsychotics. Both groups had similar mean time from admission to start of treatment (5.3 vs 5.6 days) and length of stay (12.5 vs 13.6 days), but patients in the haloperidol arm had shorter mean treatment duration compared with those using atypical antipsychotics (2.4 vs 3.9 days). [BMJ 2018;360:k1218]

Intention-to-treat analyses with the matched cohort revealed that the absolute rates of death per 100 person-days were 1.7 (129 deaths) for haloperidol and 1.1 (92 deaths) for atypical antipsychotics during 7 days of follow-up from treatment initiation.

The corresponding survival probability was 0.93 and 0.94 at day 7, accounting for the loss of follow-up due to hospital discharge. The unadjusted hazard ratio (HR) of death was 1.51 (95 percent CI, 1.22–1.85) and the adjusted HR was 1.50 (1.14–1.96).

Of note, the associated risk appeared to be strongest during the first 4 days of follow-up and decreased over time. It was no longer evident by day 5 (HR, 1.12; 0.79–1.59). As-treated analyses showed unadjusted and adjusted HRs of 1.90 (1.43–2.53) and 1.93 (1.34–2.76), respectively.

“The slightly larger HRs in as-treated analyses suggest that the potential adverse effect of haloperidol is more pronounced while patients are taking the drug compared with the time after they discontinue or switch,” researchers said.

“Given the decreasing HRs over time in the intention-to-treat analysis, it is possible that selectin of nonsusceptible patients occurs in the underlying cohort over time. Alternatively, the decreasing HR over time might also indicate that haloperidol is associated with an increased risk shortly after initiation, but not later,” they added.

Researchers explained that most ventricular arrhythmias occur during the first 48 hours following acute MI, one of the suspected mechanisms by which haloperidol heightens the risk of mortality. [JAMA 2009;301:1779-1789; J Am Geriatr Soc 2008;56:1644-1650]

“Results at later time points should be interpreted with caution, as only one-third of the cohort is left in the risk set by day 7, and less than one quarter by day 10,” they noted.

This cohort study used a nationwide sample of patient data from more than 700 hospitals across the United States. Participants included patients aged >18 years who initiated haloperidol or atypical antipsychotics (ie, olanzapine, quetiapine, risperidone) during a hospital admission with a primary diagnosis of acute MI between 2003 and 2014.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.